Home » ImmunoGen Starts Trial of Lung Cancer Drug
ImmunoGen Starts Trial of Lung Cancer Drug
ImmunoGen Inc. said it has initiated a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901, for first-line treatment of small-cell lung cancer in patients with extensive disease.
boston
boston
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May